1337 The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignancies

• Jishun Chen,
• Min Deng,
• Yun Liu,
• Peng Chen,
• Linjie Tian,
• Rong Guo,
• Bing Hou,
• Jay Mei,
• Bo Shan,
• Yunkai Zhang,
• Jiamei Luo

Affiliations

Jishun Chen

1Antengene Corporation Limited, Shanghai, China

Min Deng

School of Health Economics and Management, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China

Yun Liu

1Antengene Corporation Limited, Shanghai, China

Peng Chen

Department of Pathophysiology, Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China

Linjie Tian

1Antengene Biotech LLC, Doylestown, PA, USA

Rong Guo

Division of General Internal Medicine and Health Services Research, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA

Bing Hou

2Antengene Corporation Co., Ltd, Shanghai, China

Jay Mei

3Antengene Corporation Co., Ltd, Shaoxing, Zhejiang, China

Bo Shan

3Antengene Corporation Co., Ltd, Shaoxing, Zhejiang, China

Yunkai Zhang

1Antengene Biotech LLC, Doylestown, PA, USA

Jiamei Luo

1Antengene Corporation Limited, Shanghai, China